Regdanvimab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Regdanvimab?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19.[4] The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion.[6][7] The medicine is given by infusion (drip) into a vein.[4][8]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | Regkirona |
Other names | CT-P59 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Close
The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis.[4]
Regdanvimab was approved for medical use in the European Union in November 2021.[4][5]